• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    8/23/23 12:02:13 PM ET
    $MTAC
    Medical Specialities
    Health Care
    Get the next $MTAC alert in real time by email
    SC 13G 1 tm2324590d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    TriSalus Life Sciences Inc.

    (Name of Issuer)

     

    Common stock

    (Title of Class of Securities)

     

    89680M101

    (CUSIP Number)

     

    August 10, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 89680M101

     

    1

    Name of Reporting Person:

     

    Lombard International Assurance S.A. 

     

    2

    Check the Appropriate Box if a Member of a Group (see instructions)

    (a)     ¨     (b)     x

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Luxembourg 

    Number
    of
    Shares
    Beneficially
    Owned
    by
    Each
    Reporting
    Person
    With :
    5

    Sole Voting Power

     

    1,358,0131

    6

    Shared Voting Power

     

    None  

    7

    Sole Dispositive Power

     

    1,358,0131

    8

    Shared Dispositive Power

     

    None  

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,358,0131

    10

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ¨

    11

     

    Percent of Class Represented by Amount in Row (9)

     

    5.16%2

    12

     

    Type of Reporting Person

     

    FI 

     

     

    1            Consists of (i) 41,197 shares held directly by Lombard International Assurance S.A. – P47082 and 33,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. – P47082 as a Preferred Stock PIPE Investor, (ii) 360,478 shares held directly by Lombard International Assurance S.A. – P47083 and 365,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. – P47083 as a Preferred Stock PIPE Investor, (iii) 113,293 shares held directly by Lombard International Assurance S.A. – P47084 and 110,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. – P47084 as a Preferred Stock PIPE Investor; (iv) 237,389 shares held directly by Lombard International Assurance S.A. – P47472, (v) 28,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. – P47473 as a Preferred Stock PIPE Investor, (vi) 52,000 shares of New TriSalus Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock held by Lombard International Assurance S.A. – P69562 as a Preferred Stock PIPE Investor and (vii) 17,656 shares held directly by Lombard International Assurance S.A., policy number 2304-150035.

     

    2Represents the percentage ownership based on 26,316,681 shares of common stock of TriSalus issued and outstanding as of August 10, 2023, as reported in Issuer’s Form 8-K filed on August 16, 2023.

     

     

     

    Item 1(a). Name of Issuer.

     

    TriSalus Life Sciences Inc. (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices.

     

    6272 W. 91st Ave., Westminster, Colorado 80031

     

    Item 2(a).Names of Persons Filing.

     

    This Schedule 13G is filed on behalf of Lombard International Assurance S.A.

     

    Item 2(b).Address or Principal Business Office or, if none, Residence.

     

    Lombard International Assurance S.A.
    4, rue Lou Hemmer

    L-1748 Luxembourg
    Luxembourg

     

    Item 2(c).Citizenship.

     

    Luxembourg

     

    Item 2(d).Title of Class of Securities.

     

    Common Stock

     

    Item 2(e).CUSIP Number.

     

    8968M101

     

    Item 3.If this statement is filed pursuant to Rule 13d-1(b), or 13d-3(b) or (c), check whether the person filing is a:

     

        ¨ Not Applicable
           
      (a) ¨ Broker or dealer registered under section 15 of the Act;
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act;
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act;
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940;
           
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of
           
          the Investment Company Act of 1940;
           
      (j) x A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

     

    Item 4.Ownership:

     

    (a)Amount beneficially owned:

     

    1,358,013 shares

     

    (b)Percent of class:

     

    5.16%

     

    (c)Number of shares as to which the person has:

     

      (i)Sole power to vote or to direct the vote
      1,358,013

     

      (ii)Shared power to vote or to direct the vote
      None

     

      (iii)Sole power to dispose or to direct the vote
      1,358,013

     

      (iv)Shared power to dispose or to direct the disposition of
      None

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: Not applicable

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    Not applicable.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: 23 August 2023 Lombard International Assurance S.A.
       
      Nadine Provost – Director of Investment Administration
       
      /s/ Nadine Provost
      Signed by: Nadine Provost
      EMail: [email protected]
      Signing time: 23-08-2023 08:23:39
      IP address: 192.168.2.57
       
      Thibaut Velghe – Head of Asset Oversight
       
      /s/ Thibaut Velghe
      Signed by: Thibaut Velghe
      EMail: Thibaut [email protected]
      Signing time: 22-08-2023 16:38:19
      IP address: 192.168.2.57

     

     

    Get the next $MTAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Szela Mary T was granted 84,899 shares, increasing direct ownership by 30% to 364,862 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:44:45 PM ET
    $MTAC
    Medical Specialities
    Health Care

    Marshak Richard was granted 14,752 shares, increasing direct ownership by 118% to 27,251 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:42:18 PM ET
    $MTAC
    Medical Specialities
    Health Care

    Cox Bryan F. was granted 14,752 shares, increasing direct ownership by 21% to 86,696 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:39:58 PM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

    Advances TriSalus' Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma Provides Cash Runway through Mid-2024 to Fund Key Milestones TriSalus' Common Stock Expected to Begin Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023 TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tu

    8/10/23 4:05:00 PM ET
    $MTAC
    Medical Specialities
    Health Care

    MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders

    MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or the "Company") today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the "Business Combination") with TriSalus Life Sciences ("TriSalus"). The Special Meeting has been adjourned until 11:00 a.m. Eastern Time on August 8, 2023. The Special Meeting will still be held virtually via webcast, and stockholders may attend and participate online by visiting https://www.cstproxy.com/medtechacquisition/sm2023. Participants will be able to li

    8/2/23 5:00:00 PM ET
    $MTAC
    Medical Specialities
    Health Care

    TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

    New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (NASDAQ:MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023. TriSalus' ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) (NCT04935229) cl

    6/12/23 7:00:00 AM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    SEC Filings

    View All

    SEC Form 424B3 filed by MedTech Acquisition Corporation

    424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:23:14 PM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form 424B3 filed by MedTech Acquisition Corporation

    424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:21:58 PM ET
    $MTAC
    Medical Specialities
    Health Care

    MedTech Acquisition Corporation filed SEC Form 8-K: Leadership Update

    8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:19:33 PM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Leadership Updates

    Live Leadership Updates

    View All

    TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

    TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President, Device Technology Business. Mr. Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus' TriNav® Infusion System ("TriNav®"), including device engineering, device quality, sales, marketing, a

    2/21/23 7:00:00 AM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/29/23 8:00:07 AM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/23/23 12:02:13 PM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/22/23 8:15:18 AM ET
    $MTAC
    Medical Specialities
    Health Care